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Abstract
The particle fabrication technique PRINT® was used to fabricate monodisperse size and shape
specific poly(lactide-co-glycolide) particles loaded with the chemotherapeutic Docetaxel. The
pharmacokinetics of two cylindrical shaped particles with diameter=80nm; height=320nm
(PRINT-Doc-80×320) and d=200nm; h=200nm (PRINT-Doc-200×200) were compared to
Docetaxel in mice bearing human ovarian carcinoma SKOV-3 flank xenografts. The Docetaxel
plasma exposure was ~20-fold higher for both particles compared to docetaxel. Additionally, the
volume of distribution (Vd) of Docetaxel in PRINT formulations was ~18-fold (PRINT-
Doc-80×320) and ~33-fold (PRINT-Doc-200×200) lower than Docetaxel. The prolonged duration
of Docetaxel in plasma when dosed with PRINT formulations subsequently lead to increased
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tumor exposure of Docetaxel from 0-168 hours (~53% higher for PRINT-Doc-80×320 and ~76%
higher for PRINT-Doc-200×200 particles). PRINT-Doc-80×320 had lower exposures in the liver,
spleen and lung compared with PRINT-Doc-200×200. Thus, the use of particles with smaller
feature size may be preferred to decrease clearance by organs of the mononuclear phagocyte
system.
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Background
The application of nanotechnology to oncology explores the use of macromolecular and
nanoparticle carriers to enhance delivery of therapeutics and diagnostic agents. Desired
outcomes of nanoparticle delivery include enhanced drug solubility, extended drug half-life,
and passive targeting to solid tumors by the enhanced permeability and retention (EPR)
effect [1,2] all of which may translate to improved efficacy and decreased toxicity. Two
Food and Drug Administration (FDA) approved examples of nanoparticle formulations are
Doxil® (pegylated liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel
nanoparticle). Doxil’s advantages compared to doxorubicin are increased half-life of
doxorubicin in plasma and great tumor delivery and also reduced cardiotoxicity that was
demonstrated in a single agent phase III study [3]. Abraxane showed benefit in response rate
and progression free survival in a single agent phase III trial compared to Taxol [4]. Though
there has been success in nanomedicine, the percent of injected dose of nanoparticles that
reaches the tumor remains low, and thus further study of factors affecting nanoparticle
tumor accumulation are warranted [5].
There are many formulation techniques for nanoparticle fabrication, including self-
assembled systems such as microemulsions [6] and micelles [7], liposomes [8], emulsion/
solvent evaporation [9] and nanoprecipitation [10] based polymeric particles. Particle
compositions and fabrication techniques may vary, but nanoparticles for small molecule
chemotherapy delivery have similar design criteria [11-13]. Nanoparticles are typically sized
larger than 10 nm to avoid renal clearance and extravasation to normal tissues and are
smaller than 200 nm to reduce clearance by the liver and spleen of the mononuclear
phagocyte system (MPS) [14,15]. Although general trends have been established in desired
particle size for tumor accumulation and there have been some studies on the role of particle
size and shape on cellular uptake of particles [16-18], few studies have explored the effect of
particle shape on in vivo tumor accumulation. Geng et al demonstrated that flexible
filomicelles have longer plasma circulation times and evade the MPS [19]. Chauhan et al
have demonstrated that a rod shaped particle with a small diameter has better tumor
penetration than spherical particles of similar hydrodynamic diameter [20].
However, to date, the interdependent effect of size and shape on chemotherapeutic tumor
delivery has not been explored. In this study, we applied the PRINT® (Particle Replication
In Non wetting Templates) technology, which is a soft-lithography process, to fabricate
monodisperse populations of PLGA particles with high loadings of Docetaxel (Doc) [21].
PRINT is a top-down fabrication technique that produces size and shape specific particles
that provides the ability to understand the role of size and shape on particle distribution in
vivo [22]. Two particle shapes were used; PRINT-Doc-200×200 (PRINT-Doc-200×200) and
PRINT-Doc-80×320 cylindrical particles (PRINT-Doc-80×320). The PRINT-Doc-80×320
particle has an aspect ratio of 4:1. Though this particle has a longer length than the PRINT-
Doc-200×200 particle, the 80 nm diameter may allow the particle to transport through
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smaller pores. With both particle shapes, we demonstrated improved plasma
pharmacokinetics and tumor delivery compared to the approved clinical formulation of
Taxotere®. Additionally, differences in clearance can be seen for the two PRINT particles




Poly(D,L-lactide-co-glycolide) (lactide:glycolide 85:15, 0.65 dL/g Inherent Viscosity at
30°C) was purchased from Sigma-Aldrich. Chloroform and solvents (acetonitrile and water)
for high performance liquid chromatography (HPLC) were purchased from Fisher Scientific.
Doc was purchased from LC Laboratories. Taxotere was purchased from the University of
North Carolina at Chapel Hill hospital pharmacy for research purposes. Poly(ethylene
terephthalate) (PET) sheets (6” width) were purchased from KRS plastics. Fluorocur®,
PRINT-Doc-200×200 and PRINT-Doc-80×320 prefabricated molds and 2,000 g/mol
polyvinyl alcohol (PVOH) coated PET sheets were provided by Liquidia Technologies.
Particle Fabrication
Doc particles were fabricated following previously published methods with modification
[23]. A thin film of PLGA and Doc was deposited on a 6”×12” sheet of PET by spreading
150μL of a 10 mg/mL PLGA and 10 mg/mL Doc chloroform solution using a # 5 Mayer
Rod (R.D. Specialties). The solvent was evaporated with heat. The PET sheet with the film
was then placed in contact with the patterned side of a mold and passed through heated nips
(ChemInstruments Hot Roll Laminator) at 130°C and 80psi. The mold was split from the
PET sheet as they both passed through the hot laminator. The patterned side of the mold was
then placed in contact with a sheet of PET sheet coated with 2,000 g/mol PVOH. This was
then passed through the hot laminator to transfer the particles from the mold to the PET
sheet. The mold was then peeled from the PET sheet. The particles were removed by passing
the PVOH coated PET sheet through motorized rollers and applying water to dissolve the
PVOH to release the particles. To remove excess PVOH, the particles were purified and
then concentrated by tangential flow filtration (Spectrum Labs).
Particle Characterization
Particles were imaged by scanning electron microscopy (SEM) by pipetting a 50 μL sample
of particle on a glass slide. The sample was then dried and coated with 3 nm gold palladium
alloy using a Cressington 108 auto sputter coater. Images were taken at an accelerating
voltage of 2 kV using a Hitachi model S-4700 SEM. For size and zeta potential
measurement, dynamic light scattering (DLS) (Malvern Instruments Nano-ZS) was used.
Drug Loading
Doc was measured using an Agilent Technologies Series 1200 HPLC with a C18 reverse
phase column (Zorbax Eclipse XDB-C18, 4.6×150mm, 5 micron). A linear gradient from
100% water to 100% acetonitrile was run over 10 minutes. Then 100% acetonitrile was run
for 5 minutes. The flow rate was 1 mL/min and detection was at 210nm. Particle samples
were prepared by diluting the sample 1 in 10 with acetonitrile and mixing the sample to
break down the particle. Standards of Doc and PLGA were prepared in acetonitrile.
In Vitro Release Studies
100 μL of particle solution (200 μg/mL Doc) was placed in a mini dialysis unit with a 20k
MW cutoff and dialyzed against a stirred 1L bath of 1×PBS at 37°C. The bath was replaced
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periodically to maintain sink conditions. There were three dialysis units for each time point.
At each time point, the particle solution in each dialysis unit was removed and centrifuged to
pellet the nanoparticles. The pellet was then analyzed for the amount Doc remaining. To
determine the percent Doc released over time, the amount Doc remaining was compared to
the initial amount of Doc in the system.
SKOV-3 human ovarian carcinoma tumor xenografts
This study was done with an approved protocol with the University of North Carolina at
Chapel Hill’s Institutional Animal Care and Use Committee. All animals used were treated
humanely. SKOV-3 human ovarian carcinoma cells, acquired from ATCC, were propagated
in culture and harvested in log-phase growth. Female C.B.-17 SCID mice, aged 6-8 weeks
and 14-18 grams in body weight, were ordered from Harlan Sprague Dawley. The mice
were acclimated for 1 week prior to tumor cell injection. Cells (5.0×106 cells in 200μL
1×PBS) were injected subcutaneously (SC) into the right flank of each mouse. Tumor
volume was calculated using the formula: tumor volume (mm3) = (w2 × l)/2, where w =
width and l = length in mm of the tumor.
Pharmacokinetic study
42 days after tumor cell implantation, mice were pair matched according to tumor volume
into three treatment groups. Individual tumor volumes ranged from 40 to 253 mm3 at the
time of grouping. The dosage for Docetaxel administered was based upon previously
published work [24]. All mice received 10 mg/kg Docetaxel via a single tail vein injection.
Group 1 (n = 17) received Taxotere. Group 2 (n = 18) received PRINT-Doc-200×200.
Group 3 (n = 18) received PRINT-Doc-80×320. Formulations were diluted to 1 mg/mL of
Docetaxel with normal saline and mice were dosed at 10 μL of solution per gram of body
weight.
Mice (n=3 per time point) were sacrificed at 0.083, 1, 6, 24, 72, and 168 hours after dosing.
Blood (~1 mL) was collected via terminal cardiac puncture using sodium heparin as an
anticoagulant under CO2 anesthesia and processed for plasma by centrifugation (1,500 × g
for 5 min). Plasma and tissues were placed in cryopreservation vials and preserved by snap
freezing using liquid nitrogen. Tissues were stored at -80°C until analysis. Samples were
processed for sum total (encapsulated + released) Doc using a protein precipitation method
and analyzed by LC-MS/MS.
Sample Preparation and Processing
Total tissue and tumor weight was recorded at time of collection. Whole tissue and tumors
were snap frozen in liquid nitrogen and stored at -80°C until homogenized. To form
homogenates, the intact tissues or tumors were thawed and sectioned. The sections were
weighed and diluted in a 1:3 ratio with phosphate buffered saline (PBS) solution (assumes
tumor and tissue has a density of 1 mg/ml). Finally, these mixtures were homogenized by
placing zirconium oxide beads (15 small and 2 large) into 2 mL tubes at 3,000 × g using a
Precellys 24 homogenizer (Bertin Technologies) twice for 15 sec each with a 5 sec wait
between each run. The resulting homogenates were snap frozen in liquid nitrogen and stored
at - 80°C until processed.
Sample processing for determining plasma, tissue, or tumor concentrations of Doc was
similar and based on previously published methods [25]. Calibration standards, quality
control samples, and dilution control samples were prepared in equivalent matrix that had
demonstrated no interfering components by the addition of 10μl of a 10X solution of analyte
in acidified methanol (0.1%v/v acetic acid). Dilution controls and diluted unknown samples
were diluted 1:10 (10uL sample + 90uL appropriate matrix) prior to any processing. All
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samples, standards, and controls were processed as follows: 100μl of plasma or, tumor or
tissue homogenate was pipetted into a 96-well silanized glass insert, protein-precipitated
with the addition of 100 μl of a 50:50 mixture of methanol:acetonitrile containing the
internal standard solution (paclitaxel), vortexed for 1 min, and centrifuged for 15 min at
3,000×g at 4°C. The supernatants were analyzed by liquid chromatography with detection
by tandem mass spectrometry with no further manipulation needed.
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
A previously described LC-MS/MS analytical method was used for the quantification of
analytes [26]. A Shimadzu solvent delivery system, and an Applied Biosystems API 4000
triple quadruple mass spectrometer with an APCI ion source (Applied Biosystems) were
used for these analytical studies. Separation was accomplished using a Gemini® C18,
30×2.0 mm column, with a 5 μm particle size. The mass spectrometer was operated in
positive ion mode using multiple reaction monitoring: DOC, 808.5→527.5 m/z and
paclitaxel 854.4→286.1 m/z [26].
Pharmacokinetic Analysis
The pharmacokinetics of Taxotere, PRINT-Doc-200×200 and PRINT-Doc-80×320 in
plasma, tumor and tissue were analyzed by noncompartmental methods using WinNonlin
Professional Edition version 5.2.1 (Pharsight Corp, Cary, NC). The area under the
concentration versus time curve (AUC) was calculated using the linear up/log down rule.
AUC from 0 to t(AUC0-t) and AUC from 0 to ∞ (AUC0-∞) were calculated. Volume of
distribution (Vd) and clearance (CL) were calculated using standard equations. The
maximum concentration (Cmax), time of Cmax (Tmax), last measured concentration (Clast)
and time of Clast (Tlast) were determined by visual inspection of the concentration versus
time curve data.
Statistics
Data was analyzed for statistical differences by one-way analysis of variance (ANOVA)
followed by Bonferroni’s modified t-test for multiple comparisons using GraphPad Prism




The characteristics for the PRINT-Doc-80×320 and PRINT-Doc-200×200 particles are
shown in Table 1. The PRINT fabrication process makes highly monodisperse particles as
visualized by the SEM images (Figure 1). The particles had slightly negative zeta potential
because of the PVOH that remains associated with the particle following harvesting and
purification. During fabrication, the particles are transferred from the mold to PVOH coated
PET sheets. When the harvest sheet is dissolved with water during bead harvesting to release
the particles from the sheet to solution, PVOH is adsorbed onto the particle surface. This
slightly negative zeta potential may decrease nonspecific cellular uptake.
Particles were measured for size by DLS. Although the non-spherical particle shapes are not
ideal for DLS measurement, the recorded measurements for both particle shapes were
greater than 200 nm and the difference in hydrodynamic diameter was only ~30 nm. The
similarity of hydrodynamic diameter allows for a more fair comparison of shape effects on
drug pharmacokinetics.
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Additionally, as previously demonstrated [23], the Doc weight/weight percent loading (w/w
%) is much higher than what can currently be achieved with conventional bottom up
formulation approaches [27-30]. The PRINT-Doc-80×320 particles were loaded at a lower
w/w% than the PRINT-Doc-200×200 particles (33.5% vs 45.2%) due to the purification
process post particle fabrication. The particles were originally charged with 50% by weight
of Doc. Particles were washed with sterile water and concentrated by tangential flow
filtration, which allowed some Doc to leach. The PRINT-Doc-80×320 loses a larger
percentage of Doc during this purification process. This observation also matches the in
vitro release profile of Doc from the particles (Figure 2). The PRINT-Doc-80×320 particles
have a greater burst release than the PRINT-Doc-200×200 particles. ~60% of the Doc is
released in vitro for PRINT-Doc-80×320 particles by 3 hours compared to ~38% for the
PRINT-Doc-200×200 particles. Additionally, at 24 hours, nearly 100% of drug is released
from the PRINT-Doc-80×320 particles mean while the PRINT-Doc-200×200 particles still
hold ~27% of its cargo. The difference in release may be dictated by the particle geometry.
Per unit volume, a PRINT-Doc-80×320 particle has more surface area compared to a
PRINT-Doc-200×200 particle. This calculation assumes the PRINT-Doc-80×320 particle is
a cylinder that is 80 nm in diameter and has a length of 320 nm and assumes the PRINT-
Doc-200×200 particle is a cylinder that is 200 nm in diameter and has a length of 200 nm.
Increased surface area per unit volume leads to faster drug release.
Pharmacokinetics of PRINT particles and Taxotere
Sum total (encapsulated and released) docetaxel was measured for each organ. The
concentration versus time profiles of Taxotere, PRINT-Doc-200×200 and PRINT-
Doc-80×320 in plasma, tumor, spleen, liver and lungs are presented in Figure 3. The
pharmacokinetic parameters of Taxotere, PRINT-Doc-200×200 and PRINT-Doc-80×320 in
plasma, tumor, spleen, liver and lungs are presented in Table 2. The PRINT particles had
~20-fold higher plasma exposure as measured by AUC compared to Taxotere. The PRINT-
Doc-80×320 and PRINT-Doc-200×200 particles had ~5-fold and ~7-fold higher maximal
plasma Doc concentration than Taxotere, respectively. The difference in Cmax was
statistically significant higher for both PRINT particles compared to Taxotere (P<0.05).
Additionally, the volume of distribution was much lower for the PRINT particles compared
to Taxotere. The Vd for PRINT-Doc-80×320 and PRINT-Doc-200×200 was ~18-fold and
~33-fold, respectively, less than that of Taxotere. Encapsulation of Doc into PRINT particles
also decreased the clearance by ~24-fold compared to Taxotere.
The PRINT-Doc-80×320 and PRINT-Doc-200×200 particles had a 53% and 76% increase
in total tumor Doc exposure compared to Taxotere from 0 to 168 h. Interestingly, looking at
the tumor concentration versus time curve for 0 to 24 hours, the PRINT-Doc-80×320
particles gave a higher Doc exposure than the PRINT-Doc-200×200 particles, despite
PRINT-Doc-200×200 particles having higher exposure from 0-168 hours. The tumor
AUC0-24h for PRINT-Doc-80×320 was 20% higher than PRINT-Doc-200×200, but for
AUC0-168, the value for PRINT-Doc-200×200 particles was ~15.5% higher than that of
PRINT-Doc-80×320. Also, the maximal tumor Doc concentration was at 1 hour for the
PRINT-Doc-200×200 particles as opposed to 6 hours for the PRINT-Doc-80×320 particles.
Additionally, the docetaxel concentration at 24 hours was higher for the 80×320nm particles
compared to the 200×200nm particles (387 ng/mL versus 27 ng/mL). This indicates that the
PRINT-Doc-80×320 may have steady accumulation at the site of the tumor. The plasma
AUC for 0-24 hours and 0-168 hours of the PRINT-Doc-80×320 and PRINT-Doc-200×200
particles are similar. Thus, for the same plasma exposure from 0-24 hours, it appears that the
PRINT-Doc-80×320 is more efficient at delivering Doc to the tumor than the PRINT-
Doc-200×200 particle. However, from 0-168 hours, for similar plasma exposure, the
PRINT-Doc-200×200 gave higher Doc exposure in the tumor. The Clast of the PRINT-
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Doc-200×200 particles was higher in the tumor than the PRINT-Doc-80×320 particles.
Tweaking the PRINT-Doc-80×320 particle to decrease drug release rate may increase Doc
exposure at the tumor at longer time points.
Both particles had higher Doc exposure in the spleen and liver compared to Taxotere as
expected for a nanoparticle formulation [5,12-13]. However, the PRINT-Doc-200×200
particles had ~4.8-fold higher Doc exposure in the spleen compared to the PRINT-
Doc-80×320 particles. The maximal spleen concentration was also higher for the PRINT-
Doc-200×200 particles compared to PRINT-Doc-80×320 (18,038 ng/mL vs 32,333 ng/mL,
statistically significant). The spleen docetaxel concentration for the 200×200nm particles
was also higher than the 80×320nm particles at all times points after 5 minutes. Despite the
longer 320nm dimension, the higher aspect ratio PRINT-Doc-80×320 particle had less Doc
exposure in the spleen compared to the PRINT-Doc-200×200 particles.
The liver Doc exposure for the PRINT-Doc-200×200 particle was 1.4-fold higher than
PRINT-Doc-80×320 particles for AUC0-24h. However, the maximal concentrations were not
significantly different. The lung Doc exposure for the PRINT-Doc-200×200 particle was
also 1.4-fold higher than PRINT-Doc-80×320 particles. The PRINT-Doc-200×200 particles
also gave a higher maximal Doc concentration in the lungs compared to the PRINT-
Doc-80×320 particles, which was statistically significant. The PRINT-Doc-200×200
particles, possible due to its larger diameter, gets cleared more in organs such as the lung,
liver and spleen compared to the PRINT-Doc-80×320 particles.
Discussion
Monodisperse size and shape specific PLGA Doc nanoparticles were fabricated by the
PRINT process. These particles had very high loadings of Doc relative to other
nanoparticles of Docetaxel [27-30]. Although the role of drug loading on drug
pharmacokinetics and efficacy has not yet been established, higher drug loaded particles
allows for less of the non-active excipients to be injected. The formulations Taxotere and
Taxol may cause adverse reactions related to the surfactants used (polyoxyethylated castor
oil and tween 80) [31,32]. Thus, injecting less non active excipient relative to active drug
may increase tolerability of the formulation, especially as related to infusion related
reactions [4, 33].
The PRINT particles resulted in much higher plasma exposures of Doc compared to
Taxotere. Accordingly, the volume of distribution and clearance of the PRINT particles was
reduced related to Taxotere. Encapsulation of Doc into PRINT nanoparticles keeps the Doc
more confined to the plasma compartment to allow for longer circulation and subsequently
increased tumor accumulation. Additionally, reduced distribution to normal tissues may
enhance the tolerability of the PRINT formulation compared to Taxotere. Furthermore, the
two particles had similar plasma Doc exposure, but from 0-24 hours, the PRINT-
Doc-80×320 particle had higher tumor Doc exposure compared with PRINT-Doc-200×200.
Thus, though different particles may have longer circulation times and higher plasma drug
exposure, the shape of the particle may play a role in the efficiency of delivery to the tumor.
Because minimal amount of drug compared to total dose administered reaches the tumor,
incremental changes to improve tumor delivery and transport may prove to be worthwhile.
Shape selection may also aid in reducing nanoparticle clearance from MPS related organs
such as the spleen and liver. Despite its longer 320 nm dimension, the PRINT-Doc-80×320
particle had reduced exposure in the spleen, liver and lung than the PRINT-Doc-200×200
particle. Thus, the smallest dimension of the particle may be the determining factor of
particle clearance. On a similar note, Chauhan et al found that d = 14 nm; h = 55 nm rods
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had the same tumor transport as 13 nm PEG-coated CdSe/CdS quantum dots, and concluded
that the smallest dimension may be the determining factor in tumor transport [20]. Thus,
future particle design may be dictated by choosing smaller particle diameters for better
tumor delivery and MPS evasion.
However, though particles with smaller diameter may be preferred for enhanced passive
targeting applications, smaller particles will typically have increased drug release rates due
to increased surface to volume ratio. This likely explains the higher docetaxel levels for
PRINT-Doc-80×320 particles in the tumor from 0-24 hours, but not from 0-168 hours
compared to the PRINT-Doc-200×200 particles. Decreasing release rate may also be
preferred to keep docetaxel within the particle while the majority of particles are still
circulating within the first 24 hours after administration. Studies are currently on going to
determine the effect of drug release rate on pharmacokinetics and biodistribution in particles
of the same size that have varied release rate.
Fabrication of particles by the PRINT produces monodisperse particles of specific size and
shape that allows for the study of the effects of size and shape on drug distribution. In this
study, the effect of size and shape on Doc pharmacokinetics was studied using a higher
aspect ratio shaped PRINT-Doc-80×320 particle and a PRINT-Doc-200×200 particle. Both
particles were compared to the clinical comparator for Doc, Taxotere. The PRINT-
Doc-80×320 and PRINT-Doc-200×200 particles both resulted in much higher Doc plasma
levels and also greatly decreased distribution volume and clearance. The increase in Doc
plasma exposure due to Docparticle encapsulation led to increased tumor Doc exposure for
both particles compared to Taxotere. The PRINT-Doc-80×320 particle had higher tumor
Doc accumulation from 0-24 hours and also higher Doc plasma levels than the PRINT-
Doc-200×200 particles at24 hours. Additionally, the PRINT-Doc-80×320 particle had
significantly less Doc exposure in the spleen as well as the liver and lungs. Though both
particles had improved pharmacokinetics over Taxotere, the PRINT-Doc-80×320 particle
may be preferred for long circulation due to its smaller diameter to penetrate pores, which
results in better evasion of the MPS and higher tumor accumulation.
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Scanning electron microscopy image of (A) PRINT-Doc-200×200 particles and (B) PRINT-
Doc-80×320 particles
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Percent Docetaxel released from PRINT-Doc-80×320 and PRINT-Doc-200×200 particles
when incubated at 37°C in 1xPBS. ■ for PRINT-Doc-200×200 particles and ▲ for PRINT-
Doc-80×320 particles. N=3 measurements per time point.
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Docetaxel concentration versus time curve for (A) Tumor (0-168 hours), (B) Tumor (0-24
hours), (C) Plasma, (D) Lung, (E) Spleen and (F) Liver. Docetaxel concentration values for
each mouse are represented by ● for Taxotere, ■ for PRINT-Doc-200×200 particles and ▲
for PRINT-Doc-80×320 particles. The lines are connected by the mean value for each time
point.
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Table 1
Characterization of particles used in the pharmacokinetics study.
Particle Doc w/w% Size (nm) PDI Zeta Potential (mV)
PRINT-Doc-80×320 33.5 227 ± 10 0.18 ± 0.03 -3.2 ± 0.5
PRINT-Doc-200×200 45.2 263 ± 1.8 0.09 ± 0.01 -3.4 ± 0.5
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